123 related articles for article (PubMed ID: 23950208)
1. Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis.
Eke I; Storch K; Krause M; Cordes N
Cancer Res; 2013 Oct; 73(19):5869-79. PubMed ID: 23950208
[TBL] [Abstract][Full Text] [Related]
2. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
3. EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells.
Eke I; Schneider L; Förster C; Zips D; Kunz-Schughart LA; Cordes N
Cancer Res; 2013 Jan; 73(1):297-306. PubMed ID: 23074283
[TBL] [Abstract][Full Text] [Related]
4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
5. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.
Chung LY; Tang SJ; Sun GH; Chou TY; Yeh TS; Yu SL; Sun KH
Clin Cancer Res; 2012 Aug; 18(15):4037-47. PubMed ID: 22696230
[TBL] [Abstract][Full Text] [Related]
6. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor.
Liu L; Shao X; Gao W; Zhang Z; Liu P; Wang R; Huang P; Yin Y; Shu Y
FEBS J; 2012 Oct; 279(20):3800-12. PubMed ID: 22883469
[TBL] [Abstract][Full Text] [Related]
8. [The role of Smad4 and MAPK proteins in signal transduction pathway in non-small cell lung cancer].
Tong XD; Liu HX; Zhao HR; Xu SG; Li Y; Han LB; Zhang L
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):741-5. PubMed ID: 17366784
[TBL] [Abstract][Full Text] [Related]
9. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
[TBL] [Abstract][Full Text] [Related]
11. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.
Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R
Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner.
Liu ZB; Hou YF; Zhu J; Hu DL; Jin W; Ou ZL; Di GH; Wu J; Shen ZZ; Shao ZM
Oncogene; 2010 May; 29(20):2996-3009. PubMed ID: 20228837
[TBL] [Abstract][Full Text] [Related]
14. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
15. p190A RhoGAP is involved in EGFR pathways and promotes proliferation, invasion and migration in lung adenocarcinoma cells.
Notsuda H; Sakurada A; Endo C; Okada Y; Horii A; Shima H; Kondo T
Int J Oncol; 2013 Nov; 43(5):1569-77. PubMed ID: 24043274
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.
Tung CL; Chiu HC; Jian YJ; Jian YT; Chen CY; Syu JJ; Wo TY; Huang YJ; Tseng SC; Lin YW
Exp Cell Res; 2014 Apr; 322(2):345-54. PubMed ID: 24530475
[TBL] [Abstract][Full Text] [Related]
17. Irradiation and various cytotoxic drugs enhance tyrosine phosphorylation and beta(1)-integrin clustering in human A549 lung cancer cells in a substratum-dependent manner in vitro.
Cordes N; Beinke C; Plasswilm L; van Beuningen D
Strahlenther Onkol; 2004 Mar; 180(3):157-64. PubMed ID: 14991204
[TBL] [Abstract][Full Text] [Related]
18. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z
Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282
[TBL] [Abstract][Full Text] [Related]
19. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression.
Zheng Y; Ritzenthaler JD; Roman J; Han S
Am J Respir Cell Mol Biol; 2007 Dec; 37(6):681-90. PubMed ID: 17600315
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts.
Chen S; Liu X; Gong W; Yang H; Luo D; Zuo X; Li W; Wu P; Liu L; Xu Q; Ji A
Oncol Rep; 2013 Jan; 29(1):260-8. PubMed ID: 23117577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]